Hogan Lovells advises Novartis as it leads US$100 million investment in Pliant
Press releases
| 06
March
2020
Silicon Valley, 5 March, 2020 – A team of lawyers from Hogan Lovells has advised Novartis as it led a US$100 million Series C investment in Pliant Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies to slow or halt the progression of multiple life-threatening fibrotic diseases.
Novartis led the financing, with Redmile Group, Farallon Capital Management, Cormorant Asset Management, Surveyor Capital (a Citadel company) and Logos Capital joining the round as new investors. Existing investors participating in the financing included Eventide Asset Management, Cowen Healthcare Investments, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital and undisclosed institutional investors.
The Hogan Lovells team was led by Silicon Valley Office Managing Partner Nate Gallon, with support from San Francisco-based associate Shannon Kimball.